遠大醫藥(00512.HK)滴眼液海外III期臨床研究達臨床終點
遠大醫藥(00512.HK)公布,合作夥伴台新藥股份用於抗炎鎮痛的激素納米混懸滴眼液 APP13007 在美國開展的II期臨床研究和兩項III期臨床研究,均已順利達到臨床終點。集團擁有該產品在中國、香港和澳門地區的獨家開發和商業化權利。
結果顯示,APP13007在治療眼科術後抗炎和鎮痛方面有著顯著的有效性,且安全性良好,計劃將於今年上半年向美國食品藥品監督管理局遞交上市許可申請。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.